Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.45Last Year’s EPS
-0.8Same Quarter Last Year
Moderate Buy
Based on 15 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: 13.42%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Positive
Despite some challenges in the first quarter and international markets, Blueprint Medicines shows strong performance with significant revenue growth, successful pipeline advancements, and a solid financial position. The sentiment is largely positive, driven by the strong market reception of AYVAKIT and increased revenue guidance.Company Guidance
During the Blueprint Medicines 1Q 2025 earnings call, the company reported a 61% year-over-year increase in AYVAKIT revenue, contributing to total revenues of $149.4 million for the quarter. The revenue breakdown included $129.4 million from the U.S. and $20 million from ex-U.S. markets. Due to strong performance and favorable dynamics, Blueprint raised its revenue guidance for the year to a range of $700 million to $720 million. The company highlighted the significant potential of its two prioritized pipeline programs, elenestinib and BLU-808, and their progress in clinical trials, including the initiation of two proof-of-concept studies for BLU-808. Blueprint's strategic focus remains on expanding its prescriber base, particularly among allergists, dermatologists, and gastroenterologists, and increasing patient starts, aiming for a $2 billion revenue goal for AYVAKIT by 2030.AYVAKIT Revenue Growth
Blueprint Medicines achieved 61% year-over-year AYVAKIT revenue growth, capturing substantial commercial opportunities in systemic mastocytosis.
Raised Revenue Guidance
Due to strong performance and favorable dynamics, Blueprint Medicines raised its AYVAKIT net product revenue guidance to $700 million to $720 million for the year.
Pipeline Advancements
Initiated two proof-of-concept studies for BLU-808 in allergic rhinoconjunctivitis and chronic urticaria. Elenestinib showed potential best-in-disease profile with ongoing pivotal Harbor study.
Strong Cash Position
Blueprint Medicines maintains a strong cash position of $900 million, allowing continued investment in R&D and commercial initiatives.
Positive Market Reception
AYVAKIT has been well-received by both providers and patients, with over 95% of patients expressing high satisfaction, and prescriber base has tripled since ISM approval.
BPMC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BPMC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $89.50 | $99.25 | +10.89% |
Feb 13, 2025 | $103.56 | $95.19 | -8.08% |
Oct 30, 2024 | $83.40 | $89.24 | +7.00% |
Aug 01, 2024 | $108.30 | $100.29 | -7.40% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Blueprint Medicines (BPMC) report earnings?
Blueprint Medicines (BPMC) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is Blueprint Medicines (BPMC) earnings time?
Blueprint Medicines (BPMC) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BPMC EPS forecast?
BPMC EPS forecast for the fiscal quarter 2025 (Q2) is -0.45.